Form 4: Assembly Biosciences Director Anthony Altig Receives New Stock Option Grant

Anthony E. Altig, a Director at Assembly Biosciences, Inc. (ASMB), was granted 3,500 stock options with an exercise price of $15.81, aligning his interests with the company's long-term performance.

Summary

• Anthony E. Altig, a Director of Assembly Biosciences, Inc. (ASMB), was granted 3,500 stock options on June 5, 2025.
• The stock options have an exercise price of $15.81 per share.
• These options will vest upon the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent on continuous service.
• The expiration date for these stock options is June 5, 2035.
• Following this transaction, Mr. Altig directly beneficially owns 3,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns the director's financial interests with the long-term performance of the company and shareholder value.

Positives

• The grant of stock options to a director aligns their financial interests with the long-term performance and shareholder value of Assembly Biosciences, Inc.

Future Outlook

The stock options granted to Director Anthony E. Altig are set to vest upon the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, assuming continuous service.

Industry Context

This filing is a routine disclosure of an insider transaction, specifically the grant of equity compensation to a director, which is a common practice across industries, including biotechnology, to incentivize long-term commitment and performance.

Related Party Transactions

• Grant of 3,500 stock options to Anthony E. Altig, a Director of Assembly Biosciences, Inc., which constitutes a transaction between the company and a related party.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's interests with shareholder value, potentially leading to better long-term decision-making, but also represents potential future dilution if the options are exercised.

Next Steps

• The stock options will vest according to the specified schedule (earlier of June 5, 2026, or the 2026 annual meeting), assuming continuous service.
• Director Anthony E. Altig may choose to exercise these options at any time after vesting and before the expiration date of June 5, 2035.

Key Dates

Keywords

Assembly Biosciences, ASMB, Stock Options, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Biotechnology